

### Abstract title

Improving healthcare provision for chronic obstructive pulmonary disease (COPD) healthcare in Durham Dales Locality (DDL).

### Abstract Authors

Tracey Fletcher\*, Dilys Waller\*\*

### Context

COPD imposed a significant financial burden on the NHS nationally and accounted for one in eight emergency admissions to hospital<sup>1</sup>.

### Outline of the problem

The British Lung Foundation 'Invisible Lives' report showed County Durham Primary Care Trust had the 19<sup>th</sup> highest proportion of people at risk of future COPD-related hospital admissions and as the 7<sup>th</sup> highest COPD hotspot in the UK people in County Durham were 37% more likely to have a COPD-related admission compared with the UK average<sup>2</sup>. DDL had 2,240 COPD patients<sup>6</sup> equating to a prevalence of 2.4% compared with the UK average, 1.5%.<sup>3</sup>

### Assessment of the problem/ analysis of its causes

Primary care practices were identifying patients with COPD but were not engaging with them effectively.

### Strategy for change

A Joint Working Project between DDL and GlaxoSmithKline to improve COPD healthcare, improve the quality of life for COPD patients by raising the standard of care in primary care in line with NICE COPD Guideline 2010<sup>4</sup> and encourage patient self-management.

### Measurements of improvement

The Patient Outcome and Information Service\*\*\* (POINTS), provided by GSK, was used to measure changes in key COPD parameters. The COPD Assessment Test (CAT)<sup>5</sup> was used to measure the impact on patient lives.

### Effects of changes

Adherence to NICE standards increased by 10% from 56% (patient n=2142)<sup>6</sup> to 66% (patient n=2240)<sup>7</sup>. This was due largely to an increase in the recording of exacerbations by 40% from 18% to 58%<sup>7</sup>. Use of the CAT tool increased by 45% from 6% to 51%<sup>7</sup> meaning patients could inform the management of their COPD. DDL saw a 9% drop in COPD admissions in 2011/12 compared to the base year of 2010/11 and a drop of 14% in admissions in 12/13 compared to the base year 10/11. By comparison the rest of Durham and Darlington had a 2% drop and 4% increase in the respective years<sup>8</sup>.

### Lessons learnt

This type of project can drive sustainability within the health economy.

### Message for others

Using a robust and transparent approach to joint working, the NHS can successfully partner with GSK to improve patient care.

\* T Fletcher is an employee of GlaxoSmithKline

\*\* D Waller is a Clinical Lead in DDES Clinical Commissioning Group

\*\*\*The Patient Outcomes and Information Service (POINTS) provided by GlaxoSmithKline UK Ltd (GSK) as a service to medicine and is delivered on behalf of GSK by Quintiles.

### References

1. National Collaborating Centre for Chronic Conditions, Chronic Obstructive Pulmonary Disease. National clinical guidelines on management of chronic obstructive pulmonary disease in adults and primary and secondary care. Thorax 2004; 59 (Suppl 1): 1-232. [http://thorax.bmj.com/content/59/suppl\\_1/i1.full.pdf](http://thorax.bmj.com/content/59/suppl_1/i1.full.pdf) Accessed November 2013
2. British Lung Foundation, Invisible lives. Chronic Obstructive Pulmonary Disease (COPD) finding the missing million. November 2007
3. QOF Database 2008 <http://www.qpcontract.co.uk/browse/UK/11> Accessed November 2013
4. NICE COPD Guideline 2010, <http://publications.nice.org.uk/chronic-obstructive-pulmonary-disease-cg101> Accessed November 2013
5. COPD Assessment Tool <http://www.catestonline.co.uk/hcpanswers.htm> Accessed November 2013
6. POINTS baseline cluster report provided by Quintiles, data analysis by GSK, Dates of Preparation May 2011 UK/RESP/0039j/10
7. POINTS final cluster report provided by Quintiles, data analysis by GSK, Dates of Preparation May 2011 UK/RESP/0039j/10
8. Hospital Episode Statistics, GSK.